MoonLake Immunotherapeutics (MLTX) said Thursday it entered into an agreement for a facility of up to $500 million from Hercules Capital (HTGC).
MoonLake said that $75 million was drawn down at the transaction's close and that additional tranches will become available upon the company achieving certain milestones.
The company said the additional capital will support the expected launch of sonelokimab in 2027, additional clinical trials, and further investments for growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.